Synlett 2014; 25(2): 265-269
DOI: 10.1055/s-0033-1340281
letter
© Georg Thieme Verlag Stuttgart · New York

An Alternate Synthesis of Bosentan Monohydrate, an Endothelin Receptor Antagonist[1]

Rebelli Pradeep
a   Department of Chemistry, University College of Science, Saifabad, Osmania University, Hyderabad 500004, India   Email: yjpr_19@yahoo.com
b   Department of Chemistry, Jawaharlal Nehru Technological University College of Engineering, Hyderabad 500085, India
c   Department of Research and Development, MSN R&D Center, Pashamylaram, Medak, Andhra Pradesh 502307, India
,
Yerrabelly Jayaprakash Rao*
a   Department of Chemistry, University College of Science, Saifabad, Osmania University, Hyderabad 500004, India   Email: yjpr_19@yahoo.com
,
Yalamanchili Kumari Bharathi
b   Department of Chemistry, Jawaharlal Nehru Technological University College of Engineering, Hyderabad 500085, India
,
Porala Subbanarsimulu
c   Department of Research and Development, MSN R&D Center, Pashamylaram, Medak, Andhra Pradesh 502307, India
,
Ghojala Venkat Reddy
c   Department of Research and Development, MSN R&D Center, Pashamylaram, Medak, Andhra Pradesh 502307, India
,
Bairy Kondal Reddy
c   Department of Research and Development, MSN R&D Center, Pashamylaram, Medak, Andhra Pradesh 502307, India
› Author Affiliations
Further Information

Publication History

Received: 16 August 2013

Accepted after revision: 14 October 2013

Publication Date:
02 December 2013 (online)


Abstract

An alternate synthesis of an endothelin receptor antagonist bosentan monohydrate is reported. This new synthetic route involves the coupling of p-tert-butyl-N-[6-chloro-5-(2-methoxy-phenoxy)(2,2′-bipyrimidin)-4-yl]benzene sulfonamide with commercially available raw material (2,2-dimethyl-1,3-dioxolan-4-yl)methanol as the key step. Attractive features of this approach are its versatileness, commercial availability of raw materials, usage of eco-friendly reagents, and it efficiently provides the desired bosentan monohydrate free from reported impurities such as dimer, N-alkylated, and pyrimidinone impurities.

Supporting Information

 
  • References and Notes

  • 1 This is MSNRD communication number 008.
  • 2 Burry K, Clozel M, Fischli W, Hirth G, Loffler BM, Neidhart W, Ramuz H. US 5,292,740, 1994
  • 3 Harrington PJ, Khatri HN, Dehoff BS, Guimn MR, Boehler MA, Glaser KA. Org. Process Res. Dev. 2002; 6: 120
  • 4 Biffi G, Feliciani L, Viscardi E. WO 2010/103362 A2, 2010
  • 5 Rodriguez RS, Huguet CJ. WO 2010/12637 A1, 2010
  • 6 Raman JV, Patel S, Mistry S, Parmar B, Timbadiya M, Madam M. WO 2012073135 A1, 2012
  • 7 Vinayak G, Manojkumar B, Dattatraya S, Dattatrey K, Sushanth G, Ramesh D. WO 2012/56468 A1, 2012
  • 8 Niphade NC, Jagtap KM, Gaikawad CT, Jachak MN, Mathad VT. Org. Process Res. Dev. 2011; 15: 1382
  • 9 Shreerang J, Rashid K, Deven B, Dadasaheb S, Sanket G. US 2012/0136015A1, 2012
  • 10 Pradeep R, Jayaprakash RY, Bharathi KY, Rajashekar K, Venkat RG, Kondal RB. Lett. Org. Chem. 2013; 10: 364
  • 11 Krief A, Froidbise A. Tetrahedron 2004; 60: 7637
  • 12 Aldehyde intermediate 9 was found to be stable at r.t. in airtight polythene bags. Hence special storage and packing conditions are not required.
  • 13 HPLC Method Column: BDS Hypersil C18, 250 × 4.6 mm, 5 μm; UV, λ = 220 nm; temp: 30 °C; load: 20 μL; elution: gradient; buffer: dipotassium hydrogen orthophosphate; diluent: mobile phase A + mobile phase-B; mobile phase A: 95% buffer + 5% MeOH; mobile phase B: 95% MeOH + 5% H2O.
  • 14 GC Method for Residual Solvents Column: DB-624; length: 30 m; film thickness: 30 μm; injector temp: 140 °C; split: 1:5; detector temp: 260 °C (FID); carrier gas: helium; load: 1.0 μL; diluent: DMSO; oven temp: 40 °C; program to 130 °C at 6 °C per min; hold for 5 min; then again raised to 240 °C at 35 °C per min.